TransCon PTH治疗成人甲状旁腺功能减退症的2期随机双盲安慰剂对照试验
PaTH Forward是一项2期随机双盲安慰剂对照试验,纳入59例成人甲状旁腺功能减退症患者,评估每日TransCon PTH的安全性与疗效。至第26周,91%接受TransCon PTH的受试者摆脱标准治疗,平均24小时尿钙由基线415 mg/24h降至178 mg/24h,血钙维持正常,生活质量评分改善,未出现治疗相关严重或重度不良事件。
要点
- 至第26周91%接受TransCon PTH者摆脱活性维生素D及钙补充(钙≤500 mg/day)。
- 平均24小时尿钙由基线415 mg/24h降至178 mg/24h,同时血钙维持正常。
- TransCon PTH总体耐受良好,未报告治疗相关严重或重度不良事件。
核心结论
- TransCon PTH使多数成人甲状旁腺功能减退症患者摆脱口服活性维生素D并减少钙补充(≤500 mg/day)。
- 治疗实现血钙、血磷、尿钙及血钙磷乘积正常,并改善健康相关生活质量。
- 结果支持TransCon PTH作为成人甲状旁腺功能减退症的潜在激素替代治疗。
研究设计与样本
- 2期随机双盲安慰剂对照4周试验,并设开放标签延伸期。
- 共纳入59例甲状旁腺功能减退症患者。
- 干预为TransCon PTH 15、18或21 µg PTH(1-34)/day或安慰剂4周,随后22周延伸期剂量滴定(6-60 µg PTH[1-34]/day)。
主要发现
- 至第26周,91%接受TransCon PTH的受试者摆脱标准治疗(活性维生素D=0 μg/day且钙≤500 mg/day)。
- 平均24小时尿钙由基线415 mg/24h降至第26周178 mg/24h(n=44),同时血钙维持正常。
- 血磷及血钙磷乘积降至正常范围。
- 36项简表健康调查各维度平均评分由基线低于正常升至正常范围。
- 甲状旁腺功能减退症患者体验量表症状与影响评分至26周改善。
关键数值与推荐
- 标准治疗脱离定义:活性维生素D=0 μg/day且钙≤500 mg/day。
- 尿钙终点:24小时尿钙由基线均值415 mg/24h降至第26周178 mg/24h(n=44)。
- 延伸期TransCon PTH滴定剂量范围6-60 µg PTH(1-34)/day。
临床怎么用
- 对成人甲状旁腺功能减退症,TransCon PTH有望替代口服活性维生素D与钙补充。
- 治疗中需监测血钙、血磷、24小时尿钙及血钙磷乘积以评估达标情况。
- 关注生活质量量表变化以评估治疗获益。
局限性
- 为2期研究,样本量59例,随访至26周。
- 原文未报告各剂量组间具体比较数值。
- 长期安全性与有效性需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Hypoparathyroidism is characterized by insufficient levels of parathyroid hormone (PTH). TransCon PTH is an investigational long-acting prodrug of PTH(1-34) for the treatment of hypoparathyroidism. OBJECTIVE: This work aimed to investigate the safety, tolerability, and efficacy of daily TransCon PTH in adults with hypoparathyroidism. METHODS: This phase 2, randomized, double-blind, placebo-controlled 4-week trial with open-label extension enrolled 59 individuals with hypoparathyroidism. Interventions included TransCon PTH 15, 18, or 21 µg PTH(1-34)/day or placebo for 4 weeks, followed by a 22-week extension during which TransCon PTH dose was titrated (6-60 µg PTH[1-34]/day). RESULTS: By Week 26, 91% of participants treated with TransCon PTH achieved independence from standard of care (SoC, defined as active vitamin D = 0 μg/day and calcium [Ca] ≤ 500 mg/day). Mean 24-hour urine Ca (uCa) decreased from a baseline mean of 415 mg/24h to 178 mg/24h by Week 26 (n = 44) while normal serum Ca (sCa) was maintained and serum phosphate and serum calcium-phosphate product fell within the normal range. By Week 26, mean scores on the generic 36-Item Short Form Health Survey domains increased from below normal at baseline to within the normal range. The Hypoparathyroidism Patient Experience Scale symptom and impact scores improved through 26 weeks. TransCon PTH was well tolerated with no treatment-related serious or severe adverse events. CONCLUSION: TransCon PTH enabled independence from oral active vitamin D and reduced Ca supplements (≤ 500 mg/day) for most participants, achieving normal sCa, serum phosphate, uCa, serum calcium-phosphate product, and demonstrating improved health-related quality of life. These results support TransCon PTH as a potential hormone replacement therapy for adults with hypoparathyroidism.
引用
- Khan AA, Rejnmark L, Rubin M, et al. PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism. J Clin Endocrinol Metab. 2022. PMID: 34347093. doi:10.1210/clinem/dgab577
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。